Table 3.
Univariate logistic regression analysis of DILI development and DILI recurrence after rechallenge.
| DILI development | |||
|---|---|---|---|
| Covariate | OR | 95% CI | P value |
| Age | 1.00 | 0.98 to 1.01 | 0.7 |
| Female Sex | 1.16 | 0.74 to 1.84 | 0.5 |
| Type of treatment | 0.8 | ||
| Targeted therapy | Ref. | ||
| Immunotherapy | 1.01 | 0.64 to 1.61 | |
| Combination of classes | 0.58 | 0.09 to 1.97 | |
| Other | 0.69 | 0.11 to 2.33 | |
| DILI recurrence after Rechallenge | |||
| Covariate | OR | 95% CI | P value |
| Age | 1.01 | 0.96 to 1.07 | 0.6 |
| Female sex | 0.73 | 0.16 to 3.24 | 0.7 |
| ALT> 5x ULN | 2.70 | 0.38 to 54.9 | 0.3 |
| ALP> 2x ULN | 0.47 | 0.06 to 2.40 | 0.4 |
| ALT peak | 1.04 | 1.00 to 1.09 | 0.035 |
| ALP peak | 0.99 | 0.93 to 1.06 | 0.8 |
| Total bilirubin peak | 1.75 | 0.48 to 6.61 | 0.4 |
ALP, alkaline phosphatase; ALT, alanine aminotransferase; DILI, drug-induced liver injury; OR, odds ratio; ULN, upper limit of normal; Ref, reference.